Voreloxin, a First-in-Class Anticancer Quinolone Derivative, in Relapsed/Refractory Solid Tumors: A Report on Two Dosing Schedules
Ranjana H. Advani(Stanford Medicine), Daniel C. Adelman(University of California, San Francisco), Craig Berman(University of Arizona), Heather A. Wakelee(Palo Alto Institute), Ute Hoch(University of Arizona), Herbert I. Hurwitz(Duke Medical Center), Judith A. Fox(Sunesis (United States)), Michael S. Gordon(Pinnacle Oncology Hematology), David S. Mendelson(American Society of Clinical Oncology), N. Havrilla(University of Arizona), Jeffrey A. Silverman(University of Arizona), R. S. Allen(University of Arizona), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 45
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k